Suzanne Shusterman

Suzanne Shusterman, MD



Assistant Professor of Pediatrics, Harvard Medical School

  • Contact: 617-355-6000

Medical Services

Specialties

  • Neuroblastoma
  • Solid Tumors

Departments

  • Hematology / Oncology
  • Medicine

Languages

  • English

Programs

  • Hematology / Oncology
  • Neuroblastoma
  • Hematology / Oncology
To schedule an appointment: Call 617-355-6000

Experience and Education

Education

Undergraduate

University of Pennsylvania, 1985-89

Philadelphia, PA

Medical School

University of Massachusetts, 1989-1993

Worcester, MA

Pediatrics Internship

Boston Children's Hospital, 1993-1994

Boston, MA

Pediatrics Residency

Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, 1994-1996

Boston, MA

Pediatric Hematology/Oncology Fellowship

Children's Hospital of Philadelphia, 1997-2000

Philadelphia, PA

Certifications

  • Pediatrics, Pediatric Hematology/Oncology

Publications

Publications powered by Harvard Catalyst
  1. Krishnadas DK, Shusterman S, Bai F, Diller L, Sullivan JE, Cheerva AC, George RE, Lucas KG. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60.
  2. Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct; 61(10):1792-7.
  3. Bernson-Leung M, Ananth P, Shusterman S. Neuroblastoma presenting as facial nerve palsy and bulging tympanic membrane. Clin Pediatr (Phila). 2015 Feb; 54(2):183-5.
  4. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6.
  5. Markelewicz RJ, Lorenzen WA, Shusterman S, Grant FD, Fahey FH, Treves ST. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013 Aug; 38(8):604-7.
  6. Grupp SA, Prak EL, Boyer J, McDonald KR, Shusterman S, Thompson E, Callahan C, Jawad AF, Levine BL, June CH, Sullivan KE. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012 Dec 15; 18(24):6732-41.
  7. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7.
  8. Shusterman S, Grant FD, Lorenzen W, Davis RT, Laffin S, Drubach LA, Fahey FH, Treves ST. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011 Sep; 41(5):354-63.
  9. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 1; 17(15):5113-22.
  10. Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, Brodeur GM, Maris JM. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65.
  11. Show all
  12. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 1; 29(7):839-44.
  13. Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1; 70(23):9554-61.
  14. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75.
  15. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 1; 27(7):1020-5.
  16. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, Seiser E, Jagannathan J, Shusterman S, Bansal M, Khazi D, Winter C, Okawa E, Grant G, Cnaan A, Zhao H, Cheung NK, Gerald W, London W, Matthay KK, Brodeur GM, Maris JM. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62.
  17. Matthay K, Quach A, Franc B, Huberty J, Groshen S, Shusterman S, Veatch J, Brophy B, Yanik G, Maris JM. 131I-Metaiodobenzylguanidine(131I-MIBG) double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2006; 123.
  18. Maris JM and Shusterman S. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2006.
  19. BAnsal MM, Wang Q, Zhao H, Courtright J, King R, Rhodin N, Shusterman S and Maris JM. Expression profiling identifies BAI2, an endogenous inhibitor of angiogenesis, as a traget for somatic inactivation in high-risk neuroblastoma. Advances in Neuroblastoma Research Proceedings. 2006; 73.
  20. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):171-9.
  21. Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM, Shusterman S. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res. 2005 Apr 1; 11(7):2680-5.
  22. Bansal MM, Wang Q, Zhao H, King R, Rhodin N, Shusterman S and Maris JM. Somatic Inactivation of brain-specific angiogenesis inhibitor-2 (BAI2) during the malignant evolution of high-risk neuroblastoma. Pediatric Blood and Cancer. 2005; 44(6).
  23. Wang Q, Diskin S, Shusterman S, Rappaport E, Mosse Y, Khazi D, Winters C, Hii G, Attiyeh EF, King RL, Rhodin N, Grant G, Matthay KK, London WB and Maris JM. Genome-wide transcriptome analysis for neuroblastoma gene discovery and refinement of clinical risk group prediction. Advances in Neuroblastoma Research Proceedings. 2004; 103.
  24. Matthay KK, Huberty J, Hawkins R, Yanik G, Charron M, Groshen S, Seeger RC, Shusterman S and Maris JM. 131I-MIBG double infusiton with autologous stem cell transplant (ASCT) for neuroblastoma - a New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2004; 65.
  25. Morowitz M, Shusterman S, Mosse Y, Hii G, Winter CL, Khazi D, Wang Q, King R, Maris JM. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol. 2003 Dec; 16(12):1248-56.
  26. Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R, Henkin J. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15; 63(22):7861-9.
  27. Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res. 2003 Apr 1; 63(7):1631-5.
  28. Mosse Y, Greshock J, Khazi D, Hii G, Wang Q, Morowitz MJ, Winter C, Shusterman S, Weber BL and Maris JM. Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions. American Association for Cancer Research Proceedings. 2003; 44:1394.
  29. Fang J, Stern JW, Shusterman S, Alcorn K, Pierson G, Barr R, Pawel B, Diller L, Maris JM, and Grupp SA. Transplantation in Hematology and Oncology II. 2003; 283-98.
  30. Shusterman S, King RL, Rappaport E, Barr E and Maris JM. Discovery of antiangiogenic targets induced by chemotherapy in a murine model of human neuroblastoma. American Association for Cancer Research Proceedings Late Breaking Abstracts. 2003.
  31. Shusterman S and Manno CS. Transfusion of the patient with congenitally aquired coagulation defects. Hillyer CD and Silbersteing LE, editors. Principles of Blood Banking and Transfusion Medicine. 2003; 291-306.
  32. Keshelava N, Chen P, Waidyartatne SN, Shusterman S, Maris JM, Seeger RC, Triche TJ and Reynolds P. Increased incidence of TP53 mutations in post-treatment neuroblastomas. American Association for Cancer Research Proceedings. 2003; 44:809.
  33. Morowitz MJ, Shusterman S, Barr R, Wang Q, King R, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J and Maris JM. A reversible methionine aminopeptidase inhibitor potently inhibits growth of human neuroblastoma in xenotransplantation models. American Association fo Cancer Research Proceedings. 2003; 44:809.
  34. Maris JM and Shusterman S. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2003; 2263-76.
  35. Maris JM, Weiss MJ, Mosse Y, Hii G, Guo C, White PS, Hogarty MD, Mirensky T, Brodeur GM, Rebbeck TR, Urbanek M, Shusterman S. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002 Nov 15; 62(22):6651-8.
  36. Guo C, Wang Q, Winter CL, Hii G, Morowitz MJ, Mosse Y, Shusterman S and Maris JM. Chromosome 11q23.3-q24.1 deletions in neuroblastoma (NB). Advances in Neuroblastoma Research Proceedings. 2002; 18.
  37. Wang Q, Guo C, Hii G, Shusterman S, Mosse Y, Zhao H, Cnaan A, Hogarty MD and Maris JM. ID2 is a MYCN target gene, but expression is not correlated with MYCN gene amplification in human neuroblastomas. Advances in Neuroblastoma Research Proceedings. 2002; 50.
  38. Maris JM, Guo C, Hii G, Wang Q, Morowitz MJ, Winter C, Mosse Y and Shusterman S. A functional and expression profiling stratefy for isolating neuroblastoma (NB) supressor genes on chromosome 11. Advances in Neuroblastoma Research Proceedings. 2002; 18.
  39. Hii G, Shusterman S, Winter C, Guo C, Wang Q, Mosse Y, Morowitz MJ, Moreau L, Look AT and Maris JM. Prospective validation of real-time quantitative PCR for detection of MYCN amplifcation inprimary neuroblastoma specimens. Advances in Neuroblastoma Research Proceedings. 2002; 67.
  40. Maris JM, Guo C, Hii G, Wang Q, Morowitz MJ, Winter C, Mosse Y and Shusterman S. A combined functional and expression profiling strategy for isolating neuroblastoma suppresso genes on chromosome 11. American Association for Cancer Research Proceedings. 2002; 43:343.
  41. Shusterman S, Morowitz MJ, Grupp SA, Barr R, Pawel B, Zhao H, Wang Q, Weiss WA and Maris JM. Angiogenesis inhibition is an effective adjuvant therapeutic strategy in neuroblastoma (NB) preclinical models. Advances in Neuroblastoma Research Proceeddings. 2002; 87.
  42. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res. 2001 Apr; 7(4):977-84.
  43. Stern JW, Fang J, Shusterman S, Pierson G, Barr R, Pawel B, Diller L, Grupp SA. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32.
  44. Shusterman S, Barr R, McMahon G and Maris JM. The growth rate of human neuroblastoma xenografts is decreased through inhibition of multiple angiogenic signaling pathways with SU668. Journal of Pediatric Hematology/Oncology . 2001; 23:A1.
  45. Shusterman S, Barr r, McMahon G and Maris JM. Inhibition of the VEGF, PDGF and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts. American Association for Cancer Research Proceedings. 2001; 42:803.
  46. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease. Clinical Cancer Research. 2001; 7(4):977-84.
  47. Shusterman S, Grupp SA, Maris JM. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol. 2000 Dec; 35(6):673-6.
  48. Weiss MJ, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol. 2000 Dec; 35(6):526-30.
  49. Shusterman S, Meadows AT. Long term survivors of childhood leukemia. Curr Opin Hematol. 2000 Jul; 7(4):217-22.
  50. Shusterman S, Guo C and Maris JM. Detection of unbalanced 17q gain in human neuroblastomas by real-time quantitative PCR. American Association for Cancer Research Proceedings. 2000; 41:791.
  51. Shusterman S, Guo C and Maris JM. Use of real-time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumors. Medical and Pediatric Oncology. 2000; 35:748.
  52. Shusterman S. Microcytic Anemia. Iron Deficiency Anemia. The 5 Minute Pediatric Consult. 2000.
  53. Eggert A, Ikegaki N, Grotzer MA, Liu X, Kisselbach K, Shusterman S, Ho R, Evans AE and Brodeur GM. Effects of TRK receptor expression on angiogenesis in neuroblastoma cells. American Association for Cancer Research Proceedings. 2000; 41:791.
  54. Grupp SA, Shusterman S, Stern JW, Fang J, Pierson G, Diller L and Maris JM. Inhibitors of angiogenesis in minimal residual disease: safety post-BMT and efficacy in a preclinical model. Angiogenesis in Oncology and Hematology. 2000.
  55. Shusterman S, Grupp SA and Maris JM. Preclinical evaluation of antiangiogenic therapy with TNP-470 for human neuroblastoma. Molecular Targets and Cancer Therapeutics. 1999; 5:3812s.
  56. Shusterman S, Grupp SA, Kisselbach K and Maris JM. TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts. Journal of Pediatric Hematology/Oncology. 1999; 21:326.
  57. Shusterman S, Palmert MR. A 2.5-month-old girl with hyperbilirubinemia, hypoglycemia, and blindness. Curr Opin Pediatr. 1996 Aug; 8(4):411-6.
To schedule an appointment: Call 617-355-6000

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close